T.12.9 EARLY HEPATIC DECOMPENSATION IDENTIFIES PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH ATEZOLIZUMAB PLUS BEVACIZUMAB OR SORAFENIB AT HIGHEST RISK OF DEATH | Publicación